115 related articles for article (PubMed ID: 37977033)
21. Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance.
Rajandram R; Yap NY; Pailoor J; Razack AH; Ng KL; Ong TA; Morais C; Gobe GC
Pathology; 2014 Oct; 46(6):518-22. PubMed ID: 25158810
[TBL] [Abstract][Full Text] [Related]
22. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome.
Cuadros T; Trilla E; Sarró E; Vilà MR; Vilardell J; de Torres I; Salcedo M; López-Hellin J; Sánchez A; Ramón y Cajal S; Itarte E; Morote J; Meseguer A
Cancer Res; 2014 Mar; 74(5):1416-28. PubMed ID: 24390735
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
24. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
25. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
26. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
27. Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.
Yamamoto K; Hara T; Nakagawa T; Hirai M; Miyake H; Fujisawa M; Yano I
Target Oncol; 2018 Jun; 13(3):371-378. PubMed ID: 29633072
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical significance of a new neuroendocrine marker secretagogin in cervical neuroendocrine carcinoma.
Yu L; Suye S; Huang R; Liang Q; Fu C
J Clin Pathol; 2021 Dec; 74(12):787-795. PubMed ID: 33060116
[TBL] [Abstract][Full Text] [Related]
30. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the nuclear expression of pSer727-STAT3 as a prognostic factor in patients with clear cell renal carcinoma.
Lorente D; Arevalo J; Salcedo MT; Trilla E; de Torres I; Meseguer A; Morote J
Actas Urol Esp (Engl Ed); 2020 May; 44(4):245-250. PubMed ID: 32247519
[TBL] [Abstract][Full Text] [Related]
32. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
34. The significance of CD14 in clear cell renal cell carcinoma progression and survival prognosis.
Yap NY; Ong TA; Pailoor J; Gobe G; Rajandram R
Biomarkers; 2023 Feb; 28(1):24-31. PubMed ID: 36315054
[TBL] [Abstract][Full Text] [Related]
35. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
[TBL] [Abstract][Full Text] [Related]
36. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
37. Elevated Expression of ADAP2 is Associated With Aggressive Behavior of Human Clear-Cell Renal Cell Carcinoma and Poor Patient Survival.
Qiang Y; Wang X; Ding J; Wang Z; Li B; Ji H; Zhang X; Yang Y; Liu K; Zhang L; Ma S; Zhao D; Lu G
Clin Genitourin Cancer; 2023 Apr; 21(2):e78-e91. PubMed ID: 36127253
[TBL] [Abstract][Full Text] [Related]
38. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
39. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
40. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
